The biopharmaceutical sector did not relax in 2021. Biotechs raised record sums in private financing rounds and emerging companies went public with huge IPOs, while larger pharma players announced several billion-dollar M&A deals – even if the atmosphere for mega-mergers remained quiet.
The biopharmaceutical industry set a record in venture capital financing raised in a single year, with one quarter left to go in 2021. Drug developers raised $28bn in VC funding through to the third quarter versus $27
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?